These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 11309359)

  • 1. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.
    Yoshiji H; Kuriyama S; Kawata M; Yoshii J; Ikenaka Y; Noguchi R; Nakatani T; Tsujinoue H; Fukui H
    Clin Cancer Res; 2001 Apr; 7(4):1073-8. PubMed ID: 11309359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Yoshii J; Ikenaka Y; Noguchi R; Yanase K; Tsujinoue H; Imazu H; Fukui H
    Int J Oncol; 2002 Jun; 20(6):1227-31. PubMed ID: 12012003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis.
    Noguchi R; Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Mitoro A; Tsujinoue H; Imazu H; Masaki T; Fukui H
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6038-45. PubMed ID: 14676130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
    Yanase K; Yoshiji H; Ikenaka Y; Noguchi R; Kitade M; Kaji K; Yoshii J; Namisaki T; Yamazaki M; Asada K; Tsujimoto T; Akahane T; Uemura M; Fukui H
    Oncol Rep; 2007 Feb; 17(2):441-6. PubMed ID: 17203185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis.
    Yoshiji H; Kuriyama S; Ways DK; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Tsujinoue H; Nakatani T; Shibuya M; Fukui H
    Cancer Res; 1999 Sep; 59(17):4413-8. PubMed ID: 10485491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
    Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Hicklin DJ; Huber J; Nakatani T; Tsujinoue H; Yanase K; Imazu H; Fukui H
    Hepatology; 2002 Apr; 35(4):834-42. PubMed ID: 11915029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells.
    Yasumatsu R; Nakashima T; Masuda M; Ito A; Kuratomi Y; Nakagawa T; Komune S
    J Cancer Res Clin Oncol; 2004 Oct; 130(10):567-73. PubMed ID: 15449186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice.
    Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y
    Oncol Rep; 2005 Mar; 13(3):491-5. PubMed ID: 15706423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor.
    Middeke M; Hoffmann S; Hassan I; Wunderlich A; Hofbauer LC; Zielke A
    Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):386-92. PubMed ID: 12518248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression.
    Yoshiji H; Kuriyama S; Noguchi R; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Masaki T; Fukui H
    J Hepatol; 2005 May; 42(5):687-93. PubMed ID: 15826718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
    Yoshiji H; Kuriyama S; Fukui H
    Tumour Biol; 2002; 23(6):348-56. PubMed ID: 12677092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perindopril: possible use in cancer therapy.
    Yoshiji H; Kuriyama S; Fukui H
    Anticancer Drugs; 2002 Mar; 13(3):221-8. PubMed ID: 11984065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Yoshii J; Yamazaki M; Kikukawa M; Tsujinoue H; Nakatani T; Fukui H
    Hepatology; 1998 Dec; 28(6):1489-96. PubMed ID: 9828211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
    Yoshiji H; Kuriyama S; Noguchi R; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Akahane T; Asada K; Tsujimoto T; Uemura M; Fukui H
    Oncol Rep; 2006 Jan; 15(1):155-9. PubMed ID: 16328049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Very-low-dose combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide induces an early and sustained increase in neovascularization in rat ischemic legs.
    Silvestre JS; Kamsu-Kom N; Clergue M; Duriez M; Lévy BI
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1038-43. PubMed ID: 12438525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin.
    Nagai N; Oike Y; Izumi-Nagai K; Koto T; Satofuka S; Shinoda H; Noda K; Ozawa Y; Inoue M; Tsubota K; Ishida S
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2321-6. PubMed ID: 17460297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells.
    Benndorf R; Böger RH; Ergün S; Steenpass A; Wieland T
    Circ Res; 2003 Sep; 93(5):438-47. PubMed ID: 12881481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.